A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors. * Presence of measurable disease per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Baseline archival tumor specimen available or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. * Resolution of treatment-related toxicities. * Adequate hepatic, renal, cardiac, and hematologic function. * Additional cohort-specific criteria may apply. Exclusion Criteria: * Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose. * Has received a prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study drug. * Has had prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment. * Has received prior approved radiotherapy within 14 days of study therapy. * Has had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry. * Has an active autoimmune disease that has required systemic treatment in past 2 years. * Has an active infection requiring systemic therapy. * Has known active CNS metastases and/or carcinomatous meningitis. * Women who are pregnant or breastfeeding.